IASO Bio Announces Approval of Clinical Trial Notification for its BCMA CAR-T Product in Japan
IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announcedthe Clinical Trial Notification (CTN) for its independently developed fully human anti-BCMA CAR-T cell therapy was approved in Japan. The approval of the CTN in Japan for this product indicates that Japanese regulatory authorities have […]